The safety and tolerability of atorvastatin 10 mg in the collaborative atorvastatin diabetes study (CARDS)

Diabetes and Vascular Disease Research

Volumn 5, Issue 3, 2008, Pages 177-183

  Newman, Connie B ^a   Szarek, Michael ^b   Colhoun, Helen M ^c   Betteridge, D John ^d   Durrington, Paul N ^e   Hitman, Graham A ^f   Neil, H Andrew W ^g   Demicco, David A ^b   Auster, Sheila ^b   Fuller, John H ^h  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adverse effects of treatment; CARDS; Lipids; Statin; Trials; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ADULT; AGED; ALBUMINURIA; ALOPECIA; ANOREXIA; ARTICLE; ASTHENIA; CARCINOMA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOCRINE DISEASE; ERECTILE DYSFUNCTION; FEMALE; FLATULENCE; FOLLOW UP; GASTROINTESTINAL CARCINOMA; HEMATOLOGIC DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPESTHESIA; HYPOGLYCEMIA; INFECTION; INSOMNIA; KIDNEY FAILURE; LEG CRAMP; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUSCLE ATROPHY; MUSCLE DISEASE; MUSCULOSKELETAL DISEASE; MYALGIA; MYASTHENIA; MYOPATHY; MYOSITIS; NAUSEA; NECK PAIN; NEOPLASM; NEPHRITIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; PAIN; PARESTHESIA; PHARYNGITIS; PNEUMONIA; PRURITUS; RESPIRATORY TRACT DISEASE; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN APPENDAGE DISEASE; SKIN DISEASE; SOMNOLENCE; THORAX PAIN; TREATMENT DURATION; UROGENITAL TRACT DISEASE; VOMITING;

ADULT; AGED; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; GREAT BRITAIN; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IRELAND; MALE; MIDDLE AGED; MUSCULAR DISEASES; PRACTICE GUIDELINES AS TOPIC; PYRROLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 51749109325     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2008.029     Document Type: Article

References (32)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
2. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
3. Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361: 1149-58.
4. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
5. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
6. Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-45.
7. Amarenco P, Bogousslavsky J, Callahan A, 3rd et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355: 549-59.
8. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007;30(suppl 1):S4-S41.
9. Wood D, Wray R, Poulter N et al. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91 (suppl 5):v1-v52.
10. Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 2003;92:670-6.
11. Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006;97:61-7.
12. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291:1071-80.
13. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-96.
14. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-16.
15. Sever PS, Poulter NR, Dahlöf B et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005;28:1151-7.
16. Colhoun HM, Thomason MJ, Mackness MI et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 2002;19:201-11.
17. Thomason MJ, Colhoun HM, Livingstone SJ et al. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabet Med 2004; 21:901-05.
18. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI CLinical Advisory on the use and safety of statins. Circulation 2002;106:1024-8.
19. Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29: 1220-6.
20. Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005;28:595-9.
21. LaRosa JH, LaRosa JC. Enhancing drug compliance in lipid-lowering treatment. Arch Fam Med 2000;9:1169-75.
22. Zocor [package insert]. Whitehouse Station, NJ: Merck & Co. Inc; 2005.
23. Crestor [package insert]. Wilmington, DE: AstraZeneca; 2005.
24. Armitage J. The safety of statins in clinical practice. Lancet 2007;370: 1781-90.
25. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004;24:584-91.
26. Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Cannon CP. High-dose atorvastatin associated with worse glycemic control: A PROVE IT-TIMI 22 substudy. Circulation 2004; 110(suppl): III-834.
27. Holman RR, Neil A. Results of AFORRD trial. Diabet Med 2006; 23 (suppl 4):635.
28. Holman RR, Neil HAW, for the AFORRD Study Group. Atorvastatin in factorial with omega-3 fatty acids risk reduction in diabetes. Late-breaking presentation at the International Diabetes Federation 19th World Diabetes Congress, December 3-7, 2006, Cape Town, South Africa.
29. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29:1478-85.
30. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-39.
31. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005;46:1411-16.
32. Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med2005;3:6.